http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 16:04:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX</strong><strong>, BCTXL</strong><strong>) (TSX:BCT) (“BriaCell” or the “Company”)</strong>, a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “<strong>Shareholders</strong>”) for the year ended July 31, 2025 held on March 5, 2026 (the “<strong>Meeting</strong>”). A total of 48.31% of the Company’s issued and outstanding common shares (the “<strong>Common Shares</strong>”) were voted at the Meeting.</p> <p align="justify">At the Meeting, the Shareholders overwhelmingly voted http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Corp.+Announces+Results+of+Shareholder+Meeting/26118727.html Thu, 05 Mar 2026 16:04:00 -0500 A.09642568 A.30400265 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20371933 O.49066140 http://www.streetinsider.com/FDA/BriaCell+reports+extended+survival+in+metastatic+breast+cancer+trial/25896083.html <p>BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) announced that 9 of 25 patients treated with its Bria-IMT regimen since 2022 remain alive 18-47 months after enrollment in a Phase 2 study for metastatic breast cancer, according to a company statement.</p> <p>The clinical-stage biotechnology company reported that these survival durations exceed benchmarks for standard care therapies in similar patient populations. The patients had received a median of six prior therapies before entering the study.</p> <p>One highlighted patient, a 66-year-old woman with ER+/PR+/HER2+ metastatic breast cancer who had received 8 prior therapies including Enhertu, experienced complete resolution of temporal lobe metastasis http://www.streetinsider.com/FDA/BriaCell+reports+extended+survival+in+metastatic+breast+cancer+trial/25896083.html Tue, 27 Jan 2026 07:30:31 -0500 A.06822034 A.09642568 A.60012012 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20026344 O.20371933 O.20847516 http://www.streetinsider.com/FDA/BriaCell+reports+extended+survival+in+metastatic+breast+cancer+trial/25896083.html <p>BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) announced that 9 of 25 patients treated with its Bria-IMT regimen since 2022 remain alive 18-47 months after enrollment in a Phase 2 study for metastatic breast cancer, according to a company statement.</p> <p>The clinical-stage biotechnology company reported that these survival durations exceed benchmarks for standard care therapies in similar patient populations. The patients had received a median of six prior therapies before entering the study.</p> <p>One highlighted patient, a 66-year-old woman with ER+/PR+/HER2+ metastatic breast cancer who had received 8 prior therapies including Enhertu, experienced complete resolution of temporal lobe metastasis http://www.streetinsider.com/FDA/BriaCell+reports+extended+survival+in+metastatic+breast+cancer+trial/25896083.html Tue, 27 Jan 2026 07:30:31 -0500 A.06822034 A.09642568 A.60012012 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20026344 O.20371933 O.20847516 http://www.streetinsider.com/FDA/BriaCell+reports+extended+survival+in+metastatic+breast+cancer+trial/25896083.html <p>BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) announced that 9 of 25 patients treated with its Bria-IMT regimen since 2022 remain alive 18-47 months after enrollment in a Phase 2 study for metastatic breast cancer, according to a company statement.</p> <p>The clinical-stage biotechnology company reported that these survival durations exceed benchmarks for standard care therapies in similar patient populations. The patients had received a median of six prior therapies before entering the study.</p> <p>One highlighted patient, a 66-year-old woman with ER+/PR+/HER2+ metastatic breast cancer who had received 8 prior therapies including Enhertu, experienced complete resolution of temporal lobe metastasis http://www.streetinsider.com/FDA/BriaCell+reports+extended+survival+in+metastatic+breast+cancer+trial/25896083.html Tue, 27 Jan 2026 07:30:31 -0500 A.06822034 A.09642568 A.60012012 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20026344 O.20371933 O.20847516 http://www.streetinsider.com/FDA/BriaCell+reports+extended+survival+in+metastatic+breast+cancer+trial/25896083.html <p>BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) announced that 9 of 25 patients treated with its Bria-IMT regimen since 2022 remain alive 18-47 months after enrollment in a Phase 2 study for metastatic breast cancer, according to a company statement.</p> <p>The clinical-stage biotechnology company reported that these survival durations exceed benchmarks for standard care therapies in similar patient populations. The patients had received a median of six prior therapies before entering the study.</p> <p>One highlighted patient, a 66-year-old woman with ER+/PR+/HER2+ metastatic breast cancer who had received 8 prior therapies including Enhertu, experienced complete resolution of temporal lobe metastasis http://www.streetinsider.com/FDA/BriaCell+reports+extended+survival+in+metastatic+breast+cancer+trial/25896083.html Tue, 27 Jan 2026 07:30:31 -0500 A.06822034 A.09642568 A.60012012 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20026344 O.20371933 O.20847516 http://www.streetinsider.com/FDA/BriaCell+reports+extended+survival+in+metastatic+breast+cancer+trial/25896083.html <p>BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) announced that 9 of 25 patients treated with its Bria-IMT regimen since 2022 remain alive 18-47 months after enrollment in a Phase 2 study for metastatic breast cancer, according to a company statement.</p> <p>The clinical-stage biotechnology company reported that these survival durations exceed benchmarks for standard care therapies in similar patient populations. The patients had received a median of six prior therapies before entering the study.</p> <p>One highlighted patient, a 66-year-old woman with ER+/PR+/HER2+ metastatic breast cancer who had received 8 prior therapies including Enhertu, experienced complete resolution of temporal lobe metastasis http://www.streetinsider.com/FDA/BriaCell+reports+extended+survival+in+metastatic+breast+cancer+trial/25896083.html Tue, 27 Jan 2026 07:30:31 -0500 A.06822034 A.09642568 A.60012012 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20026344 O.20371933 O.20847516